Vanguard Group’s CalciMedica CALC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$2.69M Buy
81,560
+6,235
+8% +$122K ﹤0.01% 3469
2025
Q3
$1.14M Buy
75,325
+7,495
+11% +$108K ﹤0.01% 3752
2025
Q2
$519K Hold
67,830
﹤0.01% 3909
2025
Q1
$648K Hold
67,830
﹤0.01% 3823
2024
Q4
$1.2M Buy
67,830
+17,000
+33% +$298K ﹤0.01% 3704
2024
Q3
$1.13M Buy
50,830
+270
+0.5% +$5.93K ﹤0.01% 3733
2024
Q2
$1M Buy
50,560
+47,888
+1,792% +$1.21M ﹤0.01% 3789
2024
Q1
$55.6K Buy
+2,672
New +$61K ﹤0.01% 4307
2023
Q1
Sell
-5,999
Closed -$210K 4558
2022
Q4
$210K Buy
5,999
+3
+0.1% +$168 ﹤0.01% 4302
2022
Q3
$394K Sell
5,996
-485
-7% -$34.3K ﹤0.01% 4278
2022
Q2
$494K Sell
6,481
-27
-0.4% -$1.84K ﹤0.01% 4298
2022
Q1
$561K Buy
6,508
+340
+6% +$32.4K ﹤0.01% 4376
2021
Q4
$790K Sell
6,168
-15
-0.2% -$2.91K ﹤0.01% 4330
2021
Q3
$1.44M Buy
6,183
+35
+0.6% +$9.84K ﹤0.01% 4157
2021
Q2
$2.34M Buy
6,148
+2,736
+80% +$897K ﹤0.01% 3929
2021
Q1
$1.32M Buy
3,412
+700
+26% +$1.05M ﹤0.01% 3948
2020
Q4
$5.51M Buy
2,712
+1,283
+90% +$1.89M ﹤0.01% 3319
2020
Q3
$1.27M Buy
+1,429
New +$1.49M ﹤0.01% 3600

Other funds holding CALC

Vanguard Group's CALC Position: Q4 2025 in Review

Vanguard Group increased its CalciMedica (CALC) stake by 8.3% in Q4 2025, buying an estimated $122K and bringing the position to 81,560 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

Vanguard Group first reported a position in CALC in Q3 2020 and has held it in 18 quarters since. The position peaked at $5.51M in Q4 2020. 31 funds tracked by Wall St. Rank hold CALC as of Q4 2025.

  • Vanguard Group held 81,560 shares of CalciMedica worth $2.69M as of Q4 2025.
  • Vanguard Group bought 6,235 CalciMedica shares in Q4 2025, an estimated $122K.
  • CalciMedica made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3469 holding.
  • Vanguard Group first reported a position in CalciMedica in Q3 2020 and has held it in 18 quarters since.
  • Vanguard Group's CalciMedica position peaked at $5.51M in Q4 2020.
  • 31 funds tracked by Wall St. Rank held CalciMedica as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.